NOVN.CH

122.34

+0.86%↑

LONN.CH

506

-1.63%↓

NOVN.CH

122.34

+0.86%↑

LONN.CH

506

-1.63%↓

NOVN.CH

122.34

+0.86%↑

LONN.CH

506

-1.63%↓

NOVN.CH

122.34

+0.86%↑

LONN.CH

506

-1.63%↓

NOVN.CH

122.34

+0.86%↑

LONN.CH

506

-1.63%↓

Search

Roche Holding AG

Abrir

SetorSaúde

368.4 3.25

Visão Geral

Variação de preço das ações

24h

Atual

Mín

360.2

Máximo

370.4

Indicadores-chave

By Trading Economics

Rendimento

1.8B

5.5B

Vendas

15B

31B

P/E

Médio do Setor

22.556

121.746

Rendimento de Dividendos

2.7

Margem de lucro

17.892

Funcionários

103,249

EBITDA

1.5B

8B

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.70%

2.26%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1B

288B

Abertura anterior

365.15

Fecho anterior

368.4

Sentimento de Notícias

By Acuity

67%

33%

310 / 352 Ranking em Healthcare

Roche Holding AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de jan. de 2026, 10:07 UTC

Ganhos

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 de jan. de 2026, 07:07 UTC

Ganhos

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18 de nov. de 2025, 11:04 UTC

Grandes Movimentos do Mercado

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23 de out. de 2025, 09:32 UTC

Ganhos

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 de out. de 2025, 05:54 UTC

Ganhos

Roche Raises Full-Year Earnings Outlook

29 de jan. de 2026, 11:40 UTC

Conversa de Mercado
Ganhos

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 de jan. de 2026, 06:05 UTC

Ganhos

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 de jan. de 2026, 06:04 UTC

Ganhos

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 de jan. de 2026, 06:03 UTC

Ganhos

Roche Issues 2026 View

29 de jan. de 2026, 06:02 UTC

Ganhos

Analysts Saw 2025 Core EPS at CHF19.70

29 de jan. de 2026, 06:02 UTC

Ganhos

Roche: 2025 Core EPS CHF19.46

29 de jan. de 2026, 06:01 UTC

Ganhos

Analysts Had Seen 2025 Sales At CHF61.47B

29 de jan. de 2026, 06:01 UTC

Ganhos

Roche 2025 Sales CHF61.52B

28 de jan. de 2026, 11:22 UTC

Ganhos

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 de jan. de 2026, 11:31 UTC

Conversa de Mercado

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 de jan. de 2026, 11:24 UTC

Conversa de Mercado

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 de jan. de 2026, 09:30 UTC

Conversa de Mercado

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 de jan. de 2026, 07:52 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Roche Obesity Study Data Look Encouraging -- Market Talk

16 de jan. de 2026, 17:03 UTC

Conversa de Mercado

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 de jan. de 2026, 14:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Pharma Sector Can Spend Big on M&A -- Market Talk

22 de dez. de 2025, 08:48 UTC

Conversa de Mercado

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 de nov. de 2025, 12:47 UTC

Conversa de Mercado

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10 de nov. de 2025, 12:16 UTC

Conversa de Mercado
Ganhos

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23 de out. de 2025, 09:19 UTC

Conversa de Mercado
Ganhos

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 de out. de 2025, 09:11 UTC

Conversa de Mercado
Ganhos

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 de out. de 2025, 05:09 UTC

Ganhos

Roche 3Q Sales Up 6% At CER

23 de out. de 2025, 05:07 UTC

Ganhos

Roche 3Q Sales CHF14.92B

23 de out. de 2025, 05:07 UTC

Ganhos

Analysts Had Seen 3Q Sales At CHF15.17B

23 de out. de 2025, 05:07 UTC

Ganhos

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 de out. de 2025, 05:05 UTC

Ganhos

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

Comparação entre Pares

Variação de preço

Roche Holding AG Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

310 / 352 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat